## ImmuPharma PLC ("ImmuPharma" or the "Company")

## **Appointment of Company Secretary**

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company's Financial Controller, was appointed as Company Secretary on 15 January 2021.

## For further information please contact:

ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman Dimitri Dimitriou, Chief Executive Officer	+ 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin	+44 (0) 203 368 3550
Stanford Capital Partners (Joint Broker) Patrick Claridge John Howes	+44 (0) 203 815 8880
Bob Pountney	+44 (0) 1483 413500
SI Capital (Joint Broker) Nick Emerson	
<b>4Reliance (Euronext Growth Listing Sponsor)</b> Jean-Charles Snoy	+32 (0) 2 747 02 60
<b>Degroof Petercam (Liquidity Provider)</b> Erik De Clippel	+32 (0) 2 287 95 34
Backstage Communication	
Olivier Duquaine	+32 (0) 477 504 784

Notes to Editors
About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.